ATNM
Income statement / Annual
Last year (2023), Actinium Pharmaceuticals, Inc.'s total revenue was $81,000.00,
a decrease of 92.14% from the previous year.
In 2023, Actinium Pharmaceuticals, Inc.'s net income was -$48.82 M.
See Actinium Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$81,000.00
|
$1.03 M
|
$1.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$790,000.00 |
$699,000.00 |
$524,000.00 |
$447,000.00 |
$420,089.00 |
$50,721.00 |
$55,938.00 |
$77,523.00 |
$53,465.00 |
$0.00 |
| Gross Profit |
-$709,000.00 |
$331,000.00 |
$620,000.00 |
-$447,000.00 |
-$420,089.00 |
-$50,721.00 |
-$55,938.00 |
-$77,523.00 |
-$53,465.00 |
$0.00 |
| Gross Profit Ratio |
-8.75 |
0.32 |
0.54 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$38.67 M
|
$23.14 M
|
$18.03 M
|
$16.09 M
|
$16.55 M
|
$17.09 M
|
$17.70 M
|
$17.50 M
|
$13.31 M
|
$12.27 M
|
| General & Administrative
Expenses |
$13.33 M
|
$12.00 M
|
$8.08 M
|
$6.31 M
|
$5.52 M
|
$6.73 M
|
$9.16 M
|
$9.27 M
|
$11.46 M
|
$10.18 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$13.33 M
|
$12.00 M
|
$8.08 M
|
$6.31 M
|
$5.52 M
|
$6.73 M
|
$9.16 M
|
$9.27 M
|
$11.46 M
|
$10.18 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$55,938.00 |
$77,523.00 |
$53,465.00 |
$37,908.00 |
| Operating Expenses |
$52.00 M |
$35.13 M |
$26.11 M |
$22.39 M |
$22.07 M |
$23.83 M |
$26.91 M |
$26.85 M |
$24.83 M |
$22.48 M |
| Cost And Expenses |
$52.00 M |
$35.13 M |
$26.11 M |
$22.39 M |
$22.07 M |
$23.83 M |
$26.91 M |
$26.85 M |
$24.83 M |
$22.48 M |
| Interest Income |
$3.10 M |
$1.09 M |
$190,000.00 |
$178,000.00 |
$172,393.00 |
$173,359.00 |
$5,430.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$173,359.00 |
$5,430.00 |
$5,007.00 |
$7,868.00 |
$866.00 |
| Depreciation &
Amortization |
$790,000.00
|
$699,000.00
|
$524,000.00
|
$447,000.00
|
$420,089.00
|
$50,721.00
|
$55,938.00
|
$77,523.00
|
$53,465.00
|
$37,908.00
|
| EBITDA |
-$51.13 M
|
-$33.41 M
|
-$24.44 M
|
-$21.77 M
|
-$21.48 M
|
-$23.78 M
|
-$26.85 M
|
-$26.77 M
|
-$24.78 M
|
-$22.44 M
|
| EBITDA Ratio |
-631.23 |
-32.43 |
-21.36 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-640.99
|
-33.11
|
-21.82
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$3.10 M
|
$1.09 M
|
$190,000.00
|
$178,000.00
|
$172,393.00
|
$173,359.00
|
$309,553.00
|
$2.53 M
|
$3.80 M
|
-$2.21 M
|
| Income Before Tax |
-$48.82 M |
-$33.02 M |
-$24.77 M |
-$22.22 M |
-$21.90 M |
-$23.65 M |
-$26.60 M |
-$24.32 M |
-$21.03 M |
-$24.69 M |
| Income Before Tax Ratio
|
-602.69
|
-32.06
|
-21.66
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.09 M |
-$190,000.00 |
-$178,000.00 |
-$172,393.00 |
$173,359.00 |
-$309,553.00 |
$5,007.00 |
$7,868.00 |
$866.00 |
| Net Income |
-$48.82 M |
-$31.93 M |
-$24.58 M |
-$22.04 M |
-$21.73 M |
-$23.65 M |
-$26.60 M |
-$24.32 M |
-$21.03 M |
-$24.69 M |
| Net Income Ratio |
-602.69 |
-31 |
-21.49 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.83 |
-1.32 |
-1.2 |
-1.82 |
-4.37 |
-6.69 |
-11.96 |
-15.06 |
-16.53 |
-27.07 |
| EPS Diluted |
-1.83 |
-1.32 |
-1.2 |
-1.82 |
-4.37 |
-6.69 |
-11.96 |
-15.06 |
-16.53 |
-27.07 |
| Weighted Average Shares
Out |
$26.60 M
|
$24.14 M
|
$20.57 M
|
$12.13 M
|
$4.98 M
|
$3.53 M
|
$2.22 M
|
$1.62 M
|
$1.27 M
|
$912,115.00
|
| Weighted Average Shares
Out Diluted |
$26.60 M
|
$24.14 M
|
$20.57 M
|
$12.13 M
|
$4.98 M
|
$3.53 M
|
$2.22 M
|
$1.62 M
|
$1.27 M
|
$912,115.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
